Waldenstrom macroglobulinemia
Therapeutic area
Metabolic Disease
Rare disease
Yes
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Waldenstrom macroglobulinemia
- Therapeutic area
- Metabolic Disease
- Waldenstrom macroglobulinemia
- Waldenstrom macroglobulinemia
- Waldenstrom's macroglobulinemia
- Waldenström Macroglobulinemia
- Waldenström macroglobulinemia
- Waldenstrom's macroglobulinaemia
- Waldenstrom's syndrome
- macroglobulinemia of Waldenstrom
- Severity
- Unknown
- Genetic
- Hereditary
- Inborn Error of Metabolism
- Hematology
- Immunology
- Metabolic Disease
- Oncology
- MONDO ID
- MONDO:0100280
- Parent condition
- MONDO:0000432
Related records
Broader conditions (25)
- B-cell neoplasm
- B-cell non-Hodgkin lymphoma
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Hereditary disease
- Human disease
- Immune system disorder
- Inborn errors of metabolism
- Indolent B-cell non-Hodgkin lymphoma
- Leukocyte disorder
- Lymphoid hemopathy
- Lymphoid neoplasm
- Lymphoma
Narrower conditions (2)
- Macroglobulinemia, Waldenstrom, 1
- Macroglobulinemia, Waldenstrom, 2
Trials (524)
- 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
- 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
- 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma
- 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
- 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
- 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
- 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
- 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
- A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
- A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- A Long-term Extension Study of PCI-32765 (Ibrutinib)
- A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
- A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia
- A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
- A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies
- A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia
- A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
Approved drugs (2)
Drugs in development (65)
- Acalabrutinib Phase 2
- Agatolimod sodium Phase 1
- Alemtuzumab Phase 2
- Alvocidib hydrochloride Phase 1
- Antineoplaston A10 Phase 2
- APG-2575 Phase 1
- Bazlitoran Phase 1
- Bendamustine Phase 2
- BI-1206 Phase 1
- Bortezomib Phase 2
- Bortezomib D-mannitol Phase 2
- Carfilzomib Phase 2
- Cyclophosphamide Phase 3
- Cyclosporine Phase 3
- Daratumumab Phase 2
- Dasatinib anhydrous Phase 1
- Dexamethasone Phase 3
- Edodekin alfa Phase 2
- Enzastaurin Phase 2
- Epratuzumab Phase 2